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Stroke epidemiology and one-month fatality among an
urban population in Iran
Ahmad Delbari1,2, Reza Salman Roghani3, Sayed Shahaboddin Tabatabaei3,
Mehdi Rahgozar4, and Johan Lokk1
Objective Stroke is one of themost common causes of death
and disability in Iran. This study evaluated stroke patient
profiles with respect to rate, risk factors, and one-month
fatality.
Material andmethod A cross-sectional, hospital-based study
on all stroke patients older than 45 years admitted to hospi-
tals in the city of Qom throughout 2001.
Results Four hundred and sixty patients older than 45 years
were admitted as stroke. The annual stroke rate was esti-
mated to 338/100 000 (95% confidence interval, 300–360)
inhabitants older than 45 years. The annual rate of stroke
was 384/100 000 (95% confidence interval, 381–386) when
adjusted to the European population. Stroke subtypes were;
ischaemic infarction 75%, intracranial haemorrhage 20.7%,
subarachnoid haemorrhage 3%, and undetermined 1.3%.
Main risk factors were hypertension in 74.6% and diabetes
in 55.7%. Mortality rate was 24.6% within the first month.
Conclusion Stroke incidence was higher than in Western
countries. Hypertension and diabetesmellitus were consider-
ably more frequent in our studied stroke patients than in
other developing countries. Our findings need to be ad-
dressed in future health education programmes in Iran iden-
tifying patients at risk and focusing on more aggressive
prevention programmes to lower stroke incidence.
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Introduction
Globally, stroke is the second leading cause of death (1). Stroke
accounts for 57 million deaths each year, and is equivalent to
99% of all deaths. Over 85% of these deaths occur in low- and
middle-income-rated countries (2).
Stroke is a major public health problem in developing
countries (3). According to a recent well-designed population-
based study in Mashhad, Iran, incidence of stroke in Iran is
considerably higher than inmostWestern countries. The crude
annual incidence stroke rate of first-ever stroke was 139 per
100,000 inhabitants, and the rates adjusted to the European
population aged 45–84 years are higher than in most western
countries: 616 for brain infarction, 94 for intracerebral hae-
morrhage, and 12 for subarachnoid haemorrhage (4).
Framingham population-based stroke profile studies show
an increased knowledge of stroke trends, subtypes, risk factors,
and incidence rates in men and women (5). However, these
studies were conducted among predominantly white popula-
tions in Western countries. Recent studies have focused on
differences in stroke incidence between racial/ethnic groups.
High rates for African Americans but little data regarding
stroke risk inHispanic and/or Asian people have been available
(6). Recent data from Northern Manhattan suggest that black
people are not alone in the higher risk category and Hispanics
appear to have greater risks than Caucasians (7).
Stroke Incidence studies could provide investigators with
gender and race differences; identify the frequency of various
stroke risk factors and furnish health authorities with data to
be able to quantify the societal stroke burden (8). Both the
profile of stroke and medical practice patterns for stroke care
vary substantially from country to country, limiting the
applicability of many study results with regard to costs and
applied resource utilisation estimates. In China, the incidence
of ischemic stroke is reported higher than in most western
population (9).
Practice pattern variation is evident when examining differ-
ences in the average length of stay (LOS) at hospital between
countries. The average LOS in the United States for patients
with ischaemic stroke ranges from six- to 11 days (10, 11)
compared with the much longer LOS of 17–47 days in Canada
(12) and some countries in Europe (13, 14), and Asia (15).DOI: 10.1111/j.1747-4949.2010.00562.x
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The aim of this study was to estimate the incidence of stroke
and one-month fatality as well as to describe stroke subtypes
and the occurrence of established risk factors of stroke in a city




This study was a hospital based, cross-sectional study per-
formedon all patients over 45 yearswith stroke admitted to the
five departments of neurology and internal medicine wards
from 1 January 2001 to 1 January 2002: Kamkar, Masoumieh,
Valieasr, Golpaygani, and Nekoei Hospitals affiliated to Qom
Medical University.
This age limit was set due to the more common occurrence
of other aetiologies in lower ages and organisational reasons.
We organised the study according to the criteria for studies of
stroke incidence proposed by Sudlow et al. (16). The local
Ethics committee of Qom approved the study.
Population
Qom is a religious city in the centre of Iran with a young
population estimated to 940 151 of which 136 094 (1447%)
persons were 445 years in 2001 (17). The Iranian popula-
tion in general is younger and the overall life expectancy
(689 years) is lower compared with the European and North
American population (18).
Hospitals
Qom has five general hospitals, from where all the patients’
medical records were evaluated. These hospitals were admit-
ting and managing all stroke patients in Qom during 2001;
there were a total numbers of 872 beds in these hospitals.
Stroke patients were hospitalised in departments of neurology,
internal medicine, and general intensive care units of these
hospitals.
Definition
Strokediagnosis and stroke classification: strokewas defined as
rapidly developed signs of focal (or global) disturbance of
cerebral function lasting424 h (unless interrupted by surgery
or death), with no apparent nonvascular cause based on the
World Health Organization (WHO) definition of stroke(19).
This definition includes clinical investigation as well as ima-
ging techniques with CT scan, MRI, and thorough duplex
ultrasound examination of neck arteries (20). These investiga-
tions were used to determine themain type of stroke according
to International classification of disease, version 10 (ICD 10)
(21): brain infarction (BI) (including thrombotic and
embolic subtypes), intracerebral haemorrhage (ICH), subar-
achnoid haemorrhage (SAH), and undetermined stroke
main type (UND). Uncertain cases were those with clinical
features of stroke or SAH without confirmation from investi-
gations (19).
Case finding
All patients admitted with stroke symptoms and diagnosed as
stroke using the definition of ICD 10 classification systemwere
included. Hospitalmedical wards registers; intensive care units
and death certificates were screened with regard to stroke
diagnosis; two experienced health care personnel specifically
educated before study start performed these evaluations.
Patients were identified and medical records summarised. An
experienced nurse holding special education and training in
this field evaluated these specific checklists. They were assessed
under supervision of neurologists who categorised patients
with regard to stroke subtype and risk factor profile, and
reviewed all data.
Brain imaging was mandatory to differentiate between
ischaemic andhaemorrhagic strokes, and to rule out differential
diagnosis such as tumour, subdural haematoma, or SAH.
Stroke risk factors were recorded, including diabetes melli-
tus (DM), hypertension (HTN), cardiac disorders, current or
past history of smoking, and hyperlipidaemia as well as
demographic data, date of admission, and discharge.
The DMwas defined as a fasting blood sugar4126mg/dl, a
nonfasting blood sugar4200mg/dl or a documented history
of receiving antidiabetic drugs (22); HTN as a self-reported
history ofHTNor the use of antihypertensivemedications, or a
measured blood pressure consistently 4140/90mmHg (23);
cardiac disorders were diagnosed by a history and clinical
findings of cardiac diseases and/or ECG findings (24); hyper-
lipidaemia: abnormal fasting lipid profiles as defined by
National Cholesterol Education Program criteria (25) con-
stituted hyperlipidaemia or the use of lipid-lowering drugs.
Smokers: categorised as currently smoking, former smoker
or nonsmoker (26).
Patient follow-up
All diagnosed stroke patients were followed-up by a trained
study nurse for one-month to find case fatality, through in-
formation by telephone, mail, medical records, or the patients’
relatives.
Statistical methods
Standard descriptive statistics were used to describe the
variables, applying means, medians, and standard devia-
tions. Categorical variables were summarised as counts and
percentages.
Rates of strokes were adjusted to standard Iranian and
European populations by directmethod. To enable comparison
with other population-based studies, rate was age-adjusted
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to 45 years or older based on Iranian and European popula-
tions as standards, respectively. We calculated confidence
interval (CI) for crude rates and for rates specific for age and
gender, assuming normal distribution.
Case fatality was defined as the proportion of events that
were fatalwithin one-month of stroke onset. Statistical analysis
was performed using spss-11 software package.
Results
During the one full year, 460 patients 445 years and 37
patients o45 years were admitted and diagnosed as stroke
with an equal gender distribution, rendering a crude incidence
of 53/100 000/year. Considering that 136 094 of the entire
study population of 940 151 were 445 years, the stroke rate
in this subpopulation was estimated to 338/100 000 (95% CI,
300–360) (312/100 000 inmale and 370/100 000 in female) per
year. When adjusted to the Iranian population of 2007, the
annual rate of stroke was 354/100 000 (95%CI, 346–353) (27);
and 384/100 000 (95% CI, 381–386) when adjusted to the
European population of 2001 (Table 1) (28). Of the 460
patients, 204% had a history of previous stroke.
The mean age for all strokes was 696 and for the subtypes
thrombotic, embolic, ICH, and SAHwere 716, 671, 678, and
621, respectively. The proportions ofmain types of strokewere
BI 75%, ICH207%, SAH3%, andUND13%(Table 2). 512%
of Thrombotic strokes were female and 488% were male.
Among embolic and ICH subtypes, 396% and 526% were
female as well as 714% with SAH.
The one-month fatality rate in patients aged over 45 years
was 246%. Mean LOS in hospital was 78 days (1–40 days).
Among subtypes, Thrombotic subtype had the lowest LOS
with a mean of 717 days and SAH subtype had the highest
LOS with a mean of 123 days (Table 3).
Hypertension, DM, heart disease, hyperlipidaemia, and
smoking were found in 746%, 557%, 404%, 152%, and
Table 1 Age- and gender-specific annual rates of stroke per 100 000 population of Qom, Iran 2001
Age group years
Male Female Both genders
Cases/at risk Rate 96% CI Cases/at risk Rate 96% CI Cases/at risk Rate 96% CI
45–54 18/30650 59 31–85 36/24692 146 117–163 54/55342 98 71–122
55–64 44/20734 212 149–274 45/17329 260 213–287 99/38063 260 234–286
65–74 87/16737 520 403–617 74/15021 493 380–600 161/31758 507 461–539
75–84 70/4529 1546 1150–1850 66/3827 1725 1320–2120 136/8356 1628 1482–1758
851 11/1171 939 659–1219 19/1370 1387 1065–1695 30/2541 1181 761–1599
All ages 230/73821 312 280–340 230/62239 370 336–384 460/136060 338 300–360
ASR 1 321 317–324 380 376–384 354 346–353
ASR 2 343 339–340 414 409–411 384 381–386
ASR, age-standardized rate; ASR 1, adjusted to the 2007 Iranian population (27); ASR 2, adjusted to the 2001 European population (28).





45–54 55–64 65–74 75–84 85 Female Male
Ischaemic stroke
Thrombotic (55.2%) 14 35 104 84 17 254 71.65 (9.1) 130 124
5.5% 13.8% 40.9% 33.1% 6.7% 51.2% 48.8%
Embolic (19.8%) 14 25 22 23 7 91 67.07 (11.15) 36 55
15.4% 27.5% 24.2% 25.3% 7.7% 39.6% 60.4%
Haemorrhagic stroke
Subarachnoid (3%) 4 4 4 2 14 62.07 (10.22) 10 4
28.6% 28.6% 28.6% 14.3% 71.4% 28.6%
Intracerebral (20.7%) 11 25 29 24 6 95 67.81 (10.60) 50 45
11.6% 26.3% 30.5% 25.3% 6.3% 52.6% 47.4%
Undetermined (1.3%) 1 2 3 6 72.00 (10.66) 4 2
16.7% 33.3% 50.0% 66.7% 33.3%
Total (100%) 44 89 161 136 30 460 69.61 (10.15) 230 230
9.6% 19.3% 35% 29.6% 6.5% 50% 50%
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54%, respectively. The HTN was the main risk factor and
significantly different between ischaemic and haemorrhagic
strokes, 698% and 897%, respectively (Table 4).
Discussion
In this hospital-based, epidemiological stroke study, a crude
stroke incidence of 53/100 000/year was found; however,
338/100 00/year when calculated on persons 445 years was
observed. When adjusted to the European population, the
figurewas calculated to 384/100 000. These age standardisation
rates are a well-established WHO standard (28). This may be
due to differences in risk factors e.g. HTN is not aggressively
diagnosed and treated in Iran. The low crude incidence is likely
to be attributable to the higher proportion of younger people
in the population of Qom (845% o45 years). On an inter-
national basis, Sudlow et al. (16) have demonstrated variations
in the incidence rates in patients aged 45–84 years, ranging
from 238/100 000/year in Dijon to 627/100 000/year in Novo-
sibirsk, Russia (16).
In our study, ischaemic stroke was found in 75% of patients,
comparablewith other studies from Iranwith ischaemic strokes
ranging from 579% to 87% (29–31). These findings are also
comparable with European studies (32); however, these are
higher than in some developing countries like 70% in Senegal
(33) and 667% in Zimbabwe (34), lower than the 80% cerebral
infarction rate of strokes in the French West Indies (35).
The gender distribution was equal in our study, which
contrasted with African studies where men constitute the
major group in hospitalised stroke patients (33, 36). How-
ever, when looking at subtypes of stroke, there were more
females with haemorrhagic stroke although with low absolute
numbers.
The mean age of stroke onset in our study was 696 years,
which is in line with the findings of a Japanese study (37) but
older than reported in other studies of developing countries,
58 years in Gambia (36) and 604 years in Senegal (33).
In our study, the one-month mortality was 246%, which is
higher than that reported in developing countries and needs
consideration (38). The one-month fatality of stroke in
Western Europe has been reported to 229% in ameta-analysis
(39) and in Australia this figure was reported to be between
239% and 355% with seasonal variation (40).
Hypertension was the most common risk factor, encoun-
tered in three-out-of-four patients in line with the recently
published large European study PROFESS (41). In recent
decades, the prevalence of HTN and stroke mortality has
increased in Iran and southern Asia (42). The HTN prevalence
in Qom has been estimated to 535% of the population (43).
Considering such a common risk factor in our population, this
issue must be addressed in future cerebro- and cardiovascular
studies with a focus on risk-reducing life-style programmes.
Diabetes mellitus was the second most common risk factor
in this study, occurring in more than half of patients, while
reported in 14–383% in other studies. (35, 44, 45) This
discrepancy could be explained by the increased risk factor
exposure in the whole population with a DM prevalence
estimated to 57% vs. worldwide 28% (46). The HTN and
DM are major health problems in our population and clearly
presented in the ample occurrence of these risk factors in the
Table 3 Previous cerebrovascular accident (CVA) status, fatality rate, mean and standard deviation of length of stay (LOS) in hospital in stroke patients
Stroke subtype
Previous CVA Fatality LOS
CVA CVA1 Cure Death Others N Mean SD
Ischaemic stroke
Thrombotic 197 57 200 48 6 254 7.17 4.95
77.6% 22.4% 78.7% 18.9% 2.4%
Embolic 69 22 70 19 2 91 7.78 4.87
75.8% 24.2% 76.9% 20.9% 2.2%
Haemorrhagic stroke
Subarachnoid 11 3 9 5 14 12.29 11.62
78.6% 21.4% 64.3% 35.7
Intracerebral 84 11 54 35 6 95 9.08 7.08
88.4% 11.6% 56.8% 36.8% 6.3%
Undetermined 5 1 6 6 3.00 2.61
83.3% 16.7% 100%
Total 366 94 333 113 14 460 7.78 5.81
79.6% 20.4% 72.4% 24.6% 3.0%
Table 4 Proportion of risk factors in stroke patients (N5 460)
Risk factor n %
Hypertension 343 746
Diabetes mellitus 256 557
Heart disease 186 404
Hyperlipidaemia 70 152
Atrial fibrillation 48 104
Smoking 25 54
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stroke patients (47). Surprisingly, there were only 5% smokers
in contrast to 21% in the PROFESS study (41) possibly due to
religious belief and reluctance to inform the researchers.
Our results were hampered by some bias. With the inclusion
process attributable to the hospital-based design of the study, it
might be that some stroke patients were not identified because
they were not admitted to hospital due to minor symptoms
especially patients from surrounding suburban regions, or they
died before being admitted to hospital. In line with other stroke
incidence studies, non-observed strokeshavebeen estimatedat 5–
10% in European studies (48, 49). If these events were estimated
at 10% in our study, a stroke incidence of 372/100 000/year could
be calculated. However, our study acknowledges and shares the
view of a study from developing countries: ‘The choice is there-
fore to accept hospital data or have no data at all’ (50).
The Qom population is young with a mean age of 235 years
and o44% over 65 years and the percentage of patients
445 years is around 15% in Iran. However, stroke incidence is
comparable with most developing countries. The stroke mor-
bidity andmortality figures inour studymust have consequences
and need to be addressed in future research and health care
planning. Our observation thatHTNandDMwere considerably
more frequent in our study population than in other developing
countries must also be addressed in future research.
The findings of this research suggest that a more aggressive
stroke prevention regime with low-cost treatments addressing
risk factor reduction should be made widely available both on
primary stroke risk prevention and secondary stroke preven-
tion basis. Such intervention programmes must be sanctioned
and financed by local as well as national health care authorities
and focus on conceptualisation of health and illness so that
those involved continue to adhere to ordinations and pre-
scriptions by their medical doctors. From our results, we also
strongly advice a shift from the current nonspecified and
general care facilities in our general hospitals to the establish-
ment of stroke units and specific stroke rehabilitation centres.
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